Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Investigation of blast-induced traumatic brain injury.
Taylor PA, Ludwigsen JS, Ford CC. Taylor PA, et al. Among authors: ford cc. Brain Inj. 2014;28(7):879-95. doi: 10.3109/02699052.2014.888478. Epub 2014 Mar 21. Brain Inj. 2014. PMID: 24766453 Free PMC article.
A baseline for the multivariate comparison of resting-state networks.
Allen EA, Erhardt EB, Damaraju E, Gruner W, Segall JM, Silva RF, Havlicek M, Rachakonda S, Fries J, Kalyanam R, Michael AM, Caprihan A, Turner JA, Eichele T, Adelsheim S, Bryan AD, Bustillo J, Clark VP, Feldstein Ewing SW, Filbey F, Ford CC, Hutchison K, Jung RE, Kiehl KA, Kodituwakku P, Komesu YM, Mayer AR, Pearlson GD, Phillips JP, Sadek JR, Stevens M, Teuscher U, Thoma RJ, Calhoun VD. Allen EA, et al. Among authors: ford cc. Front Syst Neurosci. 2011 Feb 4;5:2. doi: 10.3389/fnsys.2011.00002. eCollection 2011. Front Syst Neurosci. 2011. PMID: 21442040 Free PMC article.
Cultivating the Multiple Sclerosis Workforce of the Future.
DeLuca GC, Buckle G, Cortese I, Graves JS, Halper J, Newsome SD, Sicotte N, Ford CC; FCMSC MS Mentorship Forum Participants. DeLuca GC, et al. Among authors: ford cc. Int J MS Care. 2017 May-Jun;19(3):123-130. doi: 10.7224/1537-2073.2015-068. Int J MS Care. 2017. PMID: 28603460 Free PMC article.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.
Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Voskuhl RR, et al. Among authors: ford cc. Lancet Neurol. 2016 Jan;15(1):35-46. doi: 10.1016/S1474-4422(15)00322-1. Epub 2015 Nov 29. Lancet Neurol. 2016. PMID: 26621682 Free article. Clinical Trial.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Cohen JA, et al. Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122652 Clinical Trial.
55 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page